Top 25 Independent Nursing Home Labs

Top 25 Independent Nursing Home Labs

Top 25 Independent Nursing Home Labs

There are approximately 75 independent lab companies across the United States that are focused on the nursing home market. The table below lists the top 25 companies as measured by their volume of Part B services for G0471 in 2017 (the latest year of available data). G0471 is the billing code used exclusively for blood draws taken from nursing home and home health patients.

On a consolidated basis, TridentUSA Health Services is the largest nursing home lab with combined volume of 956,153 for G0471 at five lab subsidiaries in 2017. Its total Part B payments for all testing services was $50 million in 2017.

American Health Associates (Miramar, FL) is next with volume of 851,305 for G0471 and total Part B payments of $38 million in 2017.

Gamma Healthcare (Poplar Bluff, MO) is third largest with G0471 volume of 291,566 and total Part B payments of almost $18 million in 2017. In addition, Gamma acquired the nursing home lab business of Boyce and Bynum Pathology Laboratories (Columbia, MO) in late 2018. 

Top 25 Fastest-Growing Labs by Medicare Part B Volume of Services

Quest Diagnostics Buys Assets From Bankrupt True Health

Quest Diagnostics Buys Assets From Bankrupt True Health

Quest Diagnostics Buys Assets From Bankrupt True Health

True Health and its parent company THG Holdings have finalized a bankruptcy court-approved sale of their assets to Cleveland HeartLab, a subsidiary of Quest Diagnostics, for $8.5 million.

The deal did not include True Health’s 100,000-square-foot lab in Richmond or its hundreds of employees. True Health acquired the Richmond lab when it purchased the assets of bankrupt Health Diagnostic Laboratory (HDL) for $37 million in late 2015.

HDL went bankrupt in 2015 after agreeing to pay $47 million to settle allegations that it defrauded Medicare and Medicaid by paying kickbacks to doctors in exchange for ordering its lipid test panels.

True Health filed for bankruptcy in July (see LE, August 2019) after CMS suspended all Medicare payments to the company based on “credible allegations of fraud.” According to an ongoing investigation by the OIG, True Health had set up labs inside rural hospitals that receive higher rates of
reimbursement from Medicare. From there, OIG investigators claim that True Health engaged in a kickback scheme by enlisting doctors into Management Service Organizations (MSOs) that incentivized them to send patient samples to the rural hospital labs. The OIG investigators say that
these physicians never had privileges with or visited the rural hospitals, and never provided their patients with a choice as to where to send their lab tests.

A Quest spokesman says that Quest chose not to acquire True Health’s facilities, staff, or accounts receivable “nor will we adopt its policies and business practices.” Essentially, Quest has purchased True Health’s client list and some instruments and supplies.

In the seven-month period January 1 through July 31, 2018, True Health recorded revenue of $38.5 million, equal to an annual rate of $66 million, according to its bankruptcy filings. If Quest’s Cleveland HeartLab can retain a fraction of True Health’s clients and revenue, then the $8.5 million purchase price will be a huge bargain, observes Laboratory Economics.

True Health is majority-owned by the private-equity firm The Riverside Company (New York City), while Founder and CEO Chris Grottenthaler has a 6% stake. True Health has $173 million in total liabilities. Its largest secured creditors are Monroe Capital Management (owed $123 million) and Riverside Strategic Capital (owed $34 million). True Health had initially filed for Chapter 11 bankruptcy reorganization in July, and is now likely headed for Chapter 7 liquidation.

Exagen Raises $58 Million From IPO

Exagen Raises $58 Million From IPO

Exagen Inc. (Vista, CA) completed an IPO on September 23, raising gross proceeds of $58 million from the sale of 4.14 million shares at $14 per share. Net proceeds were approximately $54 million after deducting the underwriting discounts and commissions and other IPO expenses.
Cowen, Cantor Fitzgerald and William Blair managed the IPO.

Exagen operates an 8,000-square-foot CAP-accredited lab in southern California. The company’s main product is a laboratory-developed test named AVISE CTD that was commercially launched in 2012. AVISE CTD is a blood test panel that can help doctors diagnose lupus, an autoimmune
disease that occurs when your body’s immune system attacks its own tissues and organs.

Exagen has a total of about 150 employees, including 55 sales reps who market AVISE CTD to 5,000 rheumatologists across the United States. Under an exclusive agreement, Exagen’s reps also market Janssen’s drug Simponi for the treatment of adult patients with moderate to severe rheumatic arthritis.

In the six months ended June 30, 2019, Exagen recorded a net loss of $9.8 million, unchanged from the same period a year earlier; revenue was up 35% to $19.7 million; and average reimbursement per AVISE CTD test increased by 5% to approximately $325 per test. The company has
accumulated total losses of $158 million since being formed in 2002.

Harbert Pushes For Change At Enzo

Harbert Pushes For Change At Enzo

Harbert Pushes For Change At Enzo

Funds managed by Harbert Management Corp. (HMC-Birmingham, AL) have purchased an 11.8% equity stake in Enzo Biochem Inc. (New York City) and nominated two new independent directors—Fabian Blank and Peter Clemens—to Enzo’s board. Enzo currently has a fivemember board and the next annual shareholders meeting will take place in early January 2021.

In a September 17 letter to Enzo’s shareholders, Harbert said, “For decades, Enzo has operated as a ‘lifestyle business,’ where management has seemingly placed its own personal and financial interests ahead of its shareholders’ best interests.” Harbert noted that Elazar Rabbani, PhD, age
75, has served as Enzo’s Chairman and CEO since he founded the company in 1976, while his brother in-law Barry Weiner, 68, is President, CFO and board member.

Over the past 10 years (ended August 31), Enzo’s total shareholder return has been -36% versus +199% for the Russell 2000 Index of small cap stocks and +337% for its peer group of lab and biotech companies, according to Harbert. In addition, Harbert notes that Enzo has reported operating losses every year since 2004, with cumulative negative operating income of $180 million, excluding legal expenses and settlements.

Harbert wants Enzo to sell its drug development division as well as non-core patents in its diagnostic products division.

Harbert says Enzo should focus on its clinical lab division, which operates a 44,000 square-foot lab in Long Island and 30 PSCs in New York and New Jersey. Focusing on the densely populated New York City area and prudently cutting costs could return Enzo’s lab segment to profitability,
according to Harbert.

In the nine months ended April 30, 2019, Enzo’s clinical lab division recorded an operating loss of $13.3 million versus operating income of $2.7 million for the same period a year earlier; revenue fell by 32% to $38 million as a result of pricing pressure related to PAMA and lower genetic testing volume due to increased competition.

uBiome Headed For Chapter 7 Liquidation

uBiome Headed For Chapter 7 Liquidation

uBiome Headed For Chapter 7 Liquidation

UBiome Inc. (San Francisco), which filed for Chapter 11 bankruptcy reorganization in early September, has moved to a liquidation under Chapter 7, after unsuccessful attempts to secure new loans or find a buyer.

The company was founded in 2012 and had marketed its top-selling SmartGut test directly to consumers by email and online ads. Patient test orders were signed off by remote physicians via a telemedicine service. SmartGut is a stool test that costs $2,970 and purportedly identifies microbes in the gut for patients with chronic gut conditions such as irritable bowel syndrome and Crohn’s Disease.

In late April, the FBI raided uBiome’s headquarters to investigate allegations that the company may have billed insurers using inaccurate codes to increase the likelihood of coverage and higher reimbursement. More recently, it’s come to light that the patient database used to validate Smart-Gut was populated by samples volunteered by employees and participants in an online fundraiser and were tainted by a number of specimens taken from infants and pets.